Дикловит

Quick links to important sections

Дикловит

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Дикловит

Quick Facts

Property Description
Active ingredient Diclofenac sodium, Thiamine (B1), Pyridoxine (B6), Cyanocobalamin (B12)
Form Hard capsules, Rectal suppositories
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID) and B-Vitamin Complex
General purpose Alleviation of pain and inflammation
Origin Diclofenac is synthetic; B-vitamins are essential nutrients

The Pharmacological Class of Дикловит

Дикловит is classified as a combination drug centered on the primary active ingredient, Diclofenac, which belongs to the Non-Steroidal Anti-Inflammatory Drug (NSAID) class. Diclofenac is a synthetic compound chemically identified as a phenylacetic acid derivative, used for its ability to mitigate pain, inflammation, and fever. This NSAID component is known for blocking the body’s synthesis of inflammatory mediators called prostaglandins.

Composition: Diclofenac and B-Vitamins

The unique identity of Дикловит is defined by its composition: it combines the NSAID Diclofenac sodium with the neurotropic B-vitamins, including Thiamine (B1), Pyridoxine (B6), and Cyanocobalamin (B12). The medicine is designed for systemic delivery, available in forms such as hard capsules and suppositories. The rationale for this distinct formulation is that the B-vitamins may enhance the analgesic effect when combined with Diclofenac, potentially by supporting the metabolic health and function of nerve tissue.

General Purpose: Targeting Pain and Inflammation

The general purpose of Дикловит is the symptomatic management of painful conditions that involve an inflammatory component. The formulation provides a dual therapeutic benefit: Diclofenac addresses the chemical signals of inflammation, while the added B-vitamins offer supplementary support to the nervous system. This approach is primarily used in situations requiring relief from discomfort linked to both inflammation and potential nerve-related issues.

What side effects are possible with Дикловит?

Possible Side Effects and Safety Information

The safety profile of Дикловит is primarily determined by its Non-Steroidal Anti-Inflammatory Drug (NSAID) component, Diclofenac sodium, and is based on official government regulatory classifications (e.g., EMA/SmPC, FDA).


Adverse Reaction Groupings

Adverse reactions are grouped by the affected System-Organ Class and by frequency:

Classification Examples of Reactions
Common (ge 1%) Headache, dizziness, nausea, vomiting, indigestion, abdominal pain, flatulence, and fluid retention (edema).
Rare (ge 0.01%) Gastrointestinal hemorrhage, ulceration, or perforation; asthma; hypersensitivity (allergic) reactions; hepatitis; and jaundice.
Very Rare (<0.01%) Severe skin reactions (e.g., Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis), hepatic necrosis, hepatic failure, and acute renal failure.

Serious Safety Considerations

The official labeling contains warnings for serious, potentially fatal adverse reactions:

  • Cardiovascular Thrombotic Events: An increased risk of serious events, including myocardial infarction and stroke, which may increase with the duration of use and is often observed at higher doses.
  • Gastrointestinal Complications: Risk of serious events, including bleeding, ulceration, and perforation of the GI tract, which can occur at any time during treatment and are a greater concern for older adults.

Safety-Related Restrictions

Regulatory documents establish constraints for use in specific contexts:

  • Use is contraindicated in the third trimester of pregnancy (after 30 weeks gestation) due to risk to the fetus.
  • It is also contraindicated in patients with a history of recurrent gastrointestinal bleeding/ulceration or established severe cardiac, renal, or hepatic failure.
  • The B-vitamin component, Pyridoxine ( B6), has a note that long-term use may carry a risk of neuropathy.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information

Overdose Scope (Official Regulatory Information)
Documented Manifestations Nausea, vomiting (potentially bloody or coffee-grounds like), stomach pain, and diarrhea are common initial signs of overdose. Central Nervous System (CNS) effects, including headache, dizziness, drowsiness, and ringing in the ears (tinnitus), are also documented in regulatory sources.
Severe/Life-Threatening Outcomes Official labeling highlights the risk of life-threatening events, including severe gastrointestinal bleeding, ulceration, or perforation. Other serious documented outcomes involve acute kidney injury (renal failure), seizures, and coma, particularly in severe exposures.
Population-Specific Notes Serious gastrointestinal complications carry a significantly higher risk of fatality in elderly patients. Large overdoses of the NSAID component are documented as being potentially very harmful to both adults and children.
Emergency Actions Required Seek medical help right away upon suspicion of overdose. The regulator mandates immediately calling emergency services or a poison control center. No specific antidote is known for this overdose, so treatment is officially designated as entirely symptomatic and supportive.
Management Focus Supportive care may include procedures like activated charcoal, gastric lavage, intravenous fluids, and continuous hospital monitoring of vital signs and renal function.

Connection to the overall overdose profile: Regulatory documents define the overdose profile by listing the spectrum of physiological manifestations, from initial CNS and GI symptoms to severe organ system compromise (renal, GI, CNS), which carries the risk of fatality. This progression is the direct basis for the mandated emergency-seeking conditions, which require immediate contact with emergency services for hospital monitoring and the initiation of strictly supportive treatments.

Therapeutic Uses of Дикловит

What Дикловит Treats: Main Uses and Benefits

The primary purpose of Дикловит (Diclofenac and B-Vitamins) is to provide supportive symptom management by addressing inflammatory or irritative states and discomfort. Its core application involves the relief of pain, tenderness, swelling, and stiffness caused by various inflammatory conditions, particularly those that interfere with daily functioning.

Therapeutic Domains and Benefits

This medication is commonly used for conditions presenting with acute or chronic episodes characterized by heightened symptoms. It is applied in situations involving pain and inflammation associated with conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, gouty arthritis, and painful vertebral syndromes like lumbago and sciatica. It is also relevant for supportive symptom management in episodic manifestations, including primary algomenorrhea and post-traumatic or post-surgical inflammatory edema.

In these contexts, the medicine provides support that helps ease the overall symptom burden and assists with managing physical discomfort, allowing patients to navigate difficult episodes more steadily. As a patient-centered benefit, the medication is designed to reduce the general discomfort associated with pain and swelling.

“The primary goal is to moderate distressing manifestations and provide symptomatic relief that helps patients cope more steadily with difficult episodes.”


Quick Fact: Relief for Pain and Inflammation
Symptom Focus Pain, stiffness, and swelling linked to symptoms that interfere with daily functioning.
Key Scenarios Acute back pain (lumbago), chronic arthritis flare-ups, and post-injury swelling.
Patient Benefit Helps ease overall symptom burden and helps improve day-to-day comfort during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus overview on Diclofenac

Eligibility and Restrictions for Use

Official Population Eligibility for Дикловит (Diclofenac/B-Vitamins)

Eligibility for Дикловит is strictly defined by regulatory documents, focusing primarily on the risks associated with the Non-Steroidal Anti-Inflammatory Drug (NSAID) component, Diclofenac. Use is generally approved for adults without pre-existing health contraindications.

Absolute Contraindications (Must Not Use)

Category Contraindication Entity
Hypersensitivity Known allergy to any component, aspirin, or other NSAIDs (e.g., aspirin-sensitive asthma).
Gastrointestinal Active peptic ulceration, gastrointestinal bleeding, or perforation.
Cardiovascular Established Ischaemic Heart Disease, Peripheral Arterial Disease, Cerebrovascular Disease, or Congestive Heart Failure (NYHA Class II–IV).
Specific Disease Leber's disease (due to the Vitamin B12 component).
Pregnancy At or after 30 weeks gestation (third trimester).

Restricted or Conditional Use

Use requires caution and monitoring for specific populations. This includes older adults (geriatric population) due to increased risk of serious adverse events. Patients with a history of GI bleeding or mild to moderate hepatic or renal impairment must use the medicine only after careful consideration. Use during the second trimester of pregnancy (20 to 30 weeks gestation) is restricted and limited to the lowest effective dose. Safety and efficacy are generally not established for children under 12 years of age.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Official regulatory documents detail specific interaction patterns for Diclofenac and the B-vitamin components of Дикловит. Co-administration with analgesic doses of Aspirin or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is not recommended due to a significantly increased risk of serious gastrointestinal adverse events. Furthermore, the use of Diclofenac is contraindicated in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Pharmacodynamic and Exposure Interactions

Interactions with agents that impair blood clotting, such as Anticoagulants (e.g., Warfarin) and SSRIs/SNRIs, increase the regulatory-documented risk of bleeding. Diclofenac may also diminish the effects of Antihypertensive Agents (e.g., ACE Inhibitors, ARBs) and Diuretics. Conversely, co-administration with Diclofenac is known to increase the plasma concentrations of drugs such as Lithium and Digoxin.

Interacting Agent Official Interaction Outcome
Levodopa (L-dopa) The Pyridoxine (B6) component reduces its efficacy.
CYP2C9 Inhibitors Increases Diclofenac exposure (Cmax and AUC).

Other Documented Restrictions

Use with Alcohol is associated with an increased regulatory warning for gastrointestinal bleeding. For patients taking ACE Inhibitors or ARBs, especially those who are elderly or renally impaired, the combination with Diclofenac may result in deterioration of renal function, as noted in official prescribing information.

Mechanism of Action

The mechanism of action for Дикловит is defined by the complementary effects of its two components. The Diclofenac component acts as a non-selective, reversible inhibitor of Cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. This interaction blocks the enzyme active site, interrupting the Arachidonic Acid Cascade and limiting the synthesis of prostaglandins. Prostaglandins are key chemical mediators of inflammation and fever. This action initiates a peripheral physiological dampening of pathway activation.

This mechanism is complemented by the B-vitamins (B1, B6, B12), which function as co-factors for neuronal metabolism and support nerve tissue function. By engaging two distinct pathways—chemical suppression and neuronal metabolic support—the formulation modulates overall nociceptive pathway activity. The mechanism is constrained in biological scenarios where prostaglandin synthesis is not the dominant pathway of the physiological response.

Dosage and Administration Information

The use of Дикловит, a medicine containing Diclofenac and B-Vitamins, follows established administration protocols for its core component, Diclofenac. The administration routes are oral (via hard capsules) and rectal (via suppositories). A fundamental principle of use is the application of the lowest effective dosage for the shortest duration necessary to manage symptoms.

For adults, the standard total daily dose typically ranges from 75 mg to 100 mg, with doses reaching a maximum of 150 mg of the Diclofenac component per 24 hours. The daily amount is generally divided into two or three separate administrations. Oral capsules must be swallowed whole and should not be crushed or chewed to maintain the drug’s intended release profile. Capsules may be taken with or after food.

The suppositories are intended for rectal use only and may be administered to supplement the oral dose, such as at bedtime to manage specific nocturnal discomfort. For specific patient groups, including older adults, the lowest effective dose is typically selected. Clinical caution is exercised, and the lowest effective dose is utilized in patients with hepatic or renal impairment.

Recent Clinical Evidence

Research evidence / Overview of studies for Дикловит

Evidence for Use in Acute Painful Vertebral Syndromes

Available research for the Diclofenac and B-Vitamins combination has explored its use in short-term, randomized, double-blind clinical trials (RCTs) focusing on acute painful vertebral syndromes, such as low back pain (lumbago). These studies primarily included adult patients presenting with conditions marked by functional limitations. Research examined outcomes related to physical discomfort and daily functioning, such as measured improvements in mobility.

Studies reported how symptoms evolved in the observed populations, with some trials describing patterns where patients receiving the combination were associated with earlier achievement of study-defined withdrawal criteria, compared to those receiving Diclofenac alone. Other research describes how recorded pain scores and functional measurements evolved in the observed populations.

Evidence for Use in Inflammatory Pain (Osteoarthritis and Acute Injury)

The combination was evaluated in research contexts involving pain associated with severe osteoarthritis and acute pain following lower-limb fracture or surgery. In these research scenarios, studies explored outcomes related to physical discomfort and monitored analgesic consumption (the volume of pain medication required) during periods of increased symptom activity.

Research provides insight into short-term changes in pain intensity in these acute settings. Evidence quality varies across studies when looking beyond the primary lumbago research, and subgroup findings are uncertain for many specific chronic inflammatory conditions.

Comparing the Combination to Diclofenac Monotherapy

Studies explored the combination therapy versus Diclofenac monotherapy using standardized RCTs and systematic reviews/meta-analyses. These reviews confirmed that the combination was studied for its potential to influence several patient-reported outcomes, including the duration of therapy needed to meet study-defined primary endpoints.

The published data show patterns related to a shorter treatment duration to achieve symptomatic relief in some acute low back pain populations when the combination was observed in the studies. Research has also explored differences between the groups regarding analgesic consumption.

Long-Term Studies and Follow-Up Duration

The available evidence primarily consists of short-term intervention studies. Follow-up durations in the most widely cited RCTs were generally limited, typically not extending beyond two weeks of treatment. A few studies were observed in patients over slightly longer periods, but the evidence is limited, and long-term effects are not fully established. These trials were not primarily designed to address the sustained management of chronic conditions, meaning information on the durability of measured symptom changes beyond the acute phase remains insufficient.

Key Studies & References

  1. Effect of Combined Diclofenac and B Vitamins (Thiamine, Pyridoxine, and Cyanocobalamin) for Low Back Pain Management: Systematic Review and Meta-analysis (2019)
  2. [Shortening diclofenac therapy by B vitamins. Results of a randomized double-blind study, diclofenac 50 mg versus diclofenac 50 mg plus B vitamins, in painful spinal diseases with degenerative changes] (1990)
  3. Impact of Low Back Pain on Quality of Life: Assessment by Patient Functionality Questionnaire and Treatment Results Using a Combination of Diclofenac plus B Vitamins or Diclofenac Monotherapy (2016)
  4. Clinical Study Effect of Diclofenac with B Vitamins on the Treatment of Acute Pain Originated by Lower-Limb Fracture and Surgery (2012)

Frequently Asked Questions (FAQ)

Common questions about Дикловит (FAQ)


Q: Is Дикловит the same kind of medicine as Nurofen or Aspirin?

The active ingredient Diclofenac is classified in official documents as a Non-Steroidal Anti-Inflammatory Drug (NSAID), which belongs to the same drug class as Aspirin and Ibuprofen (Nurofen). However, this medicine is a combination product that also includes B-vitamins, which makes its composition distinct from those monotherapies.


Q: Is Дикловит effective for chronic (long-term) joint pain?

Studies and official product information indicate that research evidence for this combination primarily consists of short-term intervention trials. The documents state that long-term effects are not fully established for the sustained management of chronic conditions like joint pain.


Q: Can using too much Дикловит cause other health issues?

Official safety documents caution that the risk of serious side effects, such as cardiovascular thrombotic events (like heart attack or stroke), may increase with the duration of use and when higher doses are taken. This is why regulatory guidance emphasizes the principle of using the lowest effective dose for the shortest period necessary.


Q: Can children or teenagers use Дикловит?

According to official regulatory documents, the safety and effectiveness for use in children under 12 years of age have not been established. The product’s official population eligibility is defined primarily for adults.


Q: Can Дикловит be used for pain in the hands or feet?

The official purpose of the medicine is the symptomatic management of painful conditions that involve an inflammatory component. While clinical studies often focus on conditions like low back pain, the medicine may fall under the general indications for pain relief in peripheral areas like the hands or feet.


Q: Does Дикловит have an expiration date I should watch for?

Like all pharmaceutical products, this medicine has an expiration date printed on the packaging or container to ensure it maintains its integrity and safety. Official disposal instructions advise that unused or expired medicine must be handled according to official guidelines.


Q: Is there a maximum amount of days I should use Дикловит for an acute injury?

Regulatory guidance requires that the medicine is used for the shortest duration necessary to manage symptoms. The short-term nature of the research supporting its use for acute painful conditions generally means the duration of therapy is limited.


Q: What is the main difference between Дикловит and other topical pain relievers?

The official product forms described in regulatory documents are hard capsules and rectal suppositories, which are designed for systemic absorption throughout the body. This is a fundamental difference compared to most over-the-counter topical pain relievers, which are often gels or creams intended for local action on the skin.


Q: How quickly does Дикловит usually start working after application?

Regulatory documents include clinical measurements, such as the time it takes for the maximum concentration (Tmax) of the drug to appear in the bloodstream. However, this clinical measurement provides an estimate of absorption time and is not the same as the patient’s subjective onset of symptom relief.


Q: How long does the effect of Дикловит typically last?

Clinical data, such as the drug's half-life in the body, is included in official documents. The half-life provides a clinical estimate of how long the medicine remains active, though a specific duration of symptom relief for every patient is not provided.


Q: Why do people sometimes feel a warm or cool sensation after applying Дикловит?

The official administration forms are systemic capsules and suppositories, which are swallowed or inserted. Sensory side effects like a warm or cool sensation associated with skin application are not listed in the official documents for these systemic forms.


Q: Is it common to have skin redness where I put the Дикловит gel?

The official product forms are systemic capsules and suppositories. Common side effects for systemic administration do not typically include application site skin reactions or redness.


Q: Is there a risk of getting stomach problems from using a topical medicine like Дикловит?

The official product is for systemic use (oral or rectal), which means the drug is absorbed into the bloodstream. Warnings for serious gastrointestinal complications (such as bleeding or ulceration) are associated with this systemic administration.


Q: Is it acceptable to go out in the sun after applying Дикловит?

The systemic form of the medicine does not typically list photodermatitis (a severe skin reaction to sunlight) as a common or rare adverse reaction in official documents.


Q: Does the strength (e.g., 1% vs 2%) of Дикловит gel make a big difference in results?

The official product is supplied in milligram (mg) strength in systemic capsules and suppositories, and not in percentage strengths (like 1% or 2%) that are common for topical forms. Therefore, comparisons between topical percentage strengths are not relevant to this official product.


Q: Is it necessary to rub Дикловит in until it disappears, or can I leave a thin layer?

The administration route for this medicine is either oral (swallowed whole capsules) or rectal (suppositories). The official instructions, therefore, do not include any guidance on rubbing a product into the skin.


Q: Do you wash the skin before or after applying Дикловит?

The official administration route is oral or rectal. The official directions for use do not contain instructions related to washing or preparing the skin before or after product administration.


Q: What if I forget to apply Дикловит at the scheduled time?

Regulatory product information typically contains specific guidance for patients who miss a scheduled dose. This information is highly specific to the product formulation and can be found in the official patient information leaflet.


Q: Is there any difference between the official purpose and what people actually use Дикловит for?

Official documents strictly define the approved indications for which the medicine has been evaluated and licensed. Uses beyond the officially approved indications (off-label) are not addressed or validated in regulatory materials.


Q: What should I do if I accidentally swallow some Дикловит gel?

Regulatory information indicates that professional medical help, such as contacting a poison control center, should be sought immediately if a potential overdose or accidental ingestion is suspected. This medicine's official forms are capsules and suppositories.


Q: Are there any materials (clothing, bandages) that should not touch Дикловит?

The official administration is oral or rectal. Storage instructions specify the medicine should be kept in the tightly closed original container, protected from factors like moisture and light. The official documentation does not address warnings related to clothing or bandaging coming into contact with the product.


Q: Is it true that the amount of medicine absorbed by the body is very small with Дикловит?

The drug's official forms are administered orally or rectally, which results in systemic absorption. This process means the drug reaches the bloodstream to exert its effect throughout the body, which is contrary to the limited absorption often associated with topical products.


Q: Are there specific body areas where Дикловит should never be applied?

The official administration is restricted to the mouth (swallowed) or the rectum (suppositories). Official product instructions do not cover application to other body areas.


Q: Can I apply other skin lotions or cosmetics on top of Дикловит?

The administration route is oral or rectal. Official instructions do not include information on applying other products, such as skin lotions or cosmetics, to the skin in relation to administration of this medicine.

How should Дикловит be stored and disposed of?

Storage and Disposal of Diclofenac (Дикловит)

The official storage conditions for Diclofenac-based products are defined to maintain stability and integrity. The medicine must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The product must be kept from freezing and protected from excessive heat, moisture, and light.

Security and Packaging

Requirement Status
Child Safety Must be stored out of the reach of children.
Container Store in the tightly closed original container.

Disposal Instructions

Disposal of unused or expired medicine should be handled according to official guidelines. The preferred method is to use a drug take-back program or consult a healthcare professional. Environmental release is prohibited; the medicine must not be thrown into wastewater or sewers.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Дикловит found in:

A-Z Index: